Analysts See $2.78 EPS for McKesson Corporation (MCK)

October 12, 2017 - By Marie Mckinney

 Analysts See $2.78 EPS for McKesson Corporation (MCK)
Investors sentiment decreased to 0.95 in Q2 2017. Its down 0.02, from 0.97 in 2017Q1. It worsened, as 66 investors sold McKesson Corporation shares while 305 reduced holdings. 100 funds opened positions while 253 raised stakes. 176.11 million shares or 4.62% less from 184.63 million shares in 2017Q1 were reported.
State Of Tennessee Treasury Department owns 0.06% invested in McKesson Corporation (NYSE:MCK) for 77,681 shares. Salem Inv Counselors Inc reported 0.36% of its portfolio in McKesson Corporation (NYSE:MCK). Gotham Asset Mgmt Ltd Liability Co holds 0.61% or 263,216 shares in its portfolio. Cornerstone Advsrs Inc stated it has 0.24% of its portfolio in McKesson Corporation (NYSE:MCK). Buckingham owns 0.09% invested in McKesson Corporation (NYSE:MCK) for 2,399 shares. Grp owns 70,202 shares for 0.04% of their portfolio. Girard Prtn reported 3,938 shares. Carlson Cap Mgmt invested in 2,071 shares. Cibc Asset Management owns 0.02% invested in McKesson Corporation (NYSE:MCK) for 20,004 shares. Millennium Mngmt Lc reported 316,181 shares. Secor Advsrs Lp has invested 0.15% of its portfolio in McKesson Corporation (NYSE:MCK). Moreover, Legal & General Gp Pcl has 0.18% invested in McKesson Corporation (NYSE:MCK) for 1.32M shares. Ibm Retirement Fund invested in 5,200 shares or 0.18% of the stock. Renaissance Technologies Lc, New York-based fund reported 1.00 million shares. Mercer Capital Advisers holds 0.15% in McKesson Corporation (NYSE:MCK) or 1,195 shares.

Since May 27, 2017, it had 0 insider buys, and 4 insider sales for $9.65 million activity. HAMMERGREN JOHN H had sold 19,316 shares worth $3.14 million.

Analysts expect McKesson Corporation (NYSE:MCK) to report $2.78 EPS on October, 26.They anticipate $0.16 EPS change or 5.44 % from last quarter’s $2.94 EPS. MCK’s profit would be $589.97M giving it 13.48 P/E if the $2.78 EPS is correct. After having $2.46 EPS previously, McKesson Corporation’s analysts see 13.01 % EPS growth. About 1.03 million shares traded. McKesson Corporation (NYSE:MCK) has declined 15.45% since October 13, 2016 and is downtrending. It has underperformed by 32.15% the S&P500.

McKesson Corporation (NYSE:MCK) Ratings Coverage

Among 21 analysts covering McKesson Corporation (NYSE:MCK), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. McKesson Corporation had 62 analyst reports since July 31, 2015 according to SRatingsIntel. The company was maintained on Friday, July 31 by S&P Research. The firm has “Buy” rating given on Friday, January 15 by Mizuho. The firm has “Buy” rating by Mizuho given on Tuesday, October 27. The firm earned “Mkt Perform” rating on Tuesday, January 12 by Raymond James. Standpoint Research downgraded the stock to “Hold” rating in Tuesday, April 26 report. Deutsche Bank downgraded McKesson Corporation (NYSE:MCK) rating on Friday, October 28. Deutsche Bank has “Hold” rating and $153 target. Robert W. Baird upgraded McKesson Corporation (NYSE:MCK) on Tuesday, September 19 to “Outperform” rating. The stock of McKesson Corporation (NYSE:MCK) earned “Neutral” rating by Mizuho on Tuesday, June 7. The firm has “Neutral” rating by JP Morgan given on Thursday, January 5. The company was downgraded on Tuesday, March 15 by Cowen & Co.

McKesson Corporation is engaged in delivering pharmaceuticals, medical supplies and healthcare information technology. The company has market cap of $31.82 billion. The Firm operates through two divisions: McKesson Distribution Solutions and Technology Solutions. It has a 6.71 P/E ratio. The McKesson Distribution Solutions segment distributes drugs and equipment, and health and beauty care products across North America and internationally.

More important recent McKesson Corporation (NYSE:MCK) news were published by: Seekingalpha.com which released: “High-Conviction Buybacks: McKesson” on September 20, 2017, also Seekingalpha.com published article titled: “Long Term Still Bullish On McKesson”, Twst.com published: “McKesson Corporation: Community Oncology Practices as Clinical Trial Partners” on October 09, 2017. More interesting news about McKesson Corporation (NYSE:MCK) was released by: News.Sys-Con.com and their article: “McKesson Corporation Fiscal 2018 Second Quarter Conference Call Scheduled for …” with publication date: October 05, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: